ATE24658T1 - Verfahren zur herstellung eines molkeproduktes. - Google Patents

Verfahren zur herstellung eines molkeproduktes.

Info

Publication number
ATE24658T1
ATE24658T1 AT84104253T AT84104253T ATE24658T1 AT E24658 T1 ATE24658 T1 AT E24658T1 AT 84104253 T AT84104253 T AT 84104253T AT 84104253 T AT84104253 T AT 84104253T AT E24658 T1 ATE24658 T1 AT E24658T1
Authority
AT
Austria
Prior art keywords
citrate
manufacturing
whey product
phosphate
whey
Prior art date
Application number
AT84104253T
Other languages
English (en)
Inventor
Rham Olivier De
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4237743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE24658(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Application granted granted Critical
Publication of ATE24658T1 publication Critical patent/ATE24658T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C21/00—Whey; Whey preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1425—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of whey, e.g. treatment of the UF permeate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A23J3/08—Dairy proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Water Supply & Treatment (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Dairy Products (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Peptides Or Proteins (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Braking Arrangements (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT84104253T 1983-05-13 1984-04-14 Verfahren zur herstellung eines molkeproduktes. ATE24658T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH261583 1983-05-13
EP84104253A EP0126290B2 (de) 1983-05-13 1984-04-14 Verfahren zur Herstellung eines Molkeproduktes

Publications (1)

Publication Number Publication Date
ATE24658T1 true ATE24658T1 (de) 1987-01-15

Family

ID=4237743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84104253T ATE24658T1 (de) 1983-05-13 1984-04-14 Verfahren zur herstellung eines molkeproduktes.

Country Status (17)

Country Link
US (1) US4748034A (de)
EP (1) EP0126290B2 (de)
JP (1) JPS59216544A (de)
AT (1) ATE24658T1 (de)
AU (1) AU564405B2 (de)
CA (1) CA1200416A (de)
DE (1) DE3461886D1 (de)
DK (1) DK235584D0 (de)
ES (1) ES532469A0 (de)
GB (1) GB2139630B (de)
HK (1) HK73787A (de)
KE (1) KE3728A (de)
MX (1) MX167579B (de)
MY (1) MY100729A (de)
NZ (1) NZ208086A (de)
SG (1) SG35687G (de)
ZA (1) ZA843213B (de)

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672230A5 (de) 1987-10-15 1989-11-15 Nestle Sa
FR2634104B1 (fr) * 1988-07-18 1991-10-18 Union Coop Agricole Hydrolysat partiel de proteines de lactoserum, procede enzymatique de preparation de cet hydrolysat, et aliment lacte dietetique hypoallergenique le contenant
DE4002204A1 (de) * 1990-01-26 1991-08-01 Westfalen Milchwerke Diaetetisches nahrungsmittel fuer patienten mit niereninsuffizienz
NL9001692A (nl) * 1990-04-26 1991-11-18 Cooeperatieve Melkproductenbed Werkwijze voor de bereiding van een olie-in-water emulsie.
JP3065116B2 (ja) * 1991-02-25 2000-07-12 株式会社第一化成 透明な乳清タンパク質加工品の製造法
JP3059595B2 (ja) * 1992-11-20 2000-07-04 森永乳業株式会社 沈澱を生じない乳清蛋白質分解物の製造法
US5350590A (en) * 1992-12-15 1994-09-27 Beatreme Foods Inc. Protein fat replacer and method of manufacture thereof
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
DK1493439T3 (da) 1997-04-02 2012-01-30 Brigham & Womens Hospital Middel til fastlæggelse af en persons risikoprofil for aterosklerotisk sygdom
PT1096952E (pt) 1998-07-15 2008-08-27 Brigham & Womens Hospital Composições de polissacáridos para a prevenção de infecções causadas por staphylococcus
US6106874A (en) * 1998-11-18 2000-08-22 Abbott Laboratories Calcium fortified juice-based nutritional supplement and process of making
MXPA02008070A (es) 2000-02-17 2004-04-05 Welch Foods Inc Productos basados en uvas, fortificados con calcio y metodos para elaborarlos.
AU2001243512C1 (en) 2000-03-08 2008-04-17 Massachusetts Institute Of Technology Heparinase III and uses thereof
CA2404858A1 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
RU2174756C1 (ru) * 2000-09-18 2001-10-20 Борисов Александр Борисович Пищевой продукт
DE10062056A1 (de) * 2000-12-15 2002-07-04 Henkel Ecolab Gmbh & Co Ohg Verfahren zur Reinigung von Ionenaustauscher-Kunststoffharzen
EP1992335A1 (de) 2001-11-01 2008-11-19 Nektar Therapeutics Sprühtrocknungsverfahren und Zusammensetzungen dafür
ES2291406T3 (es) * 2001-11-26 2008-03-01 Nestec S.A. Composicion nutritiva auto-estable, que contiene proteina de suero lacteo, intacta, procedimiento de fabricacion y uso.
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
EP1483283A4 (de) 2002-03-13 2007-04-11 Signum Biosciences Inc Modulation der proteinmethylierung und phosphoproteinphosphat
JP3833129B2 (ja) * 2002-03-19 2006-10-11 株式会社Ａｄｅｋａ 濃縮牛乳状組成物
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CA2508870C (en) 2002-12-30 2012-10-16 Novartis Ag Prefilming atomizer
US7399496B2 (en) * 2003-02-07 2008-07-15 Glanbia Nutritionals (Ireland) Limited Hydrolyzed whey protein compositions
WO2004078928A2 (en) 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
CA2534816A1 (en) 2003-06-12 2004-12-23 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
JP2007502991A (ja) 2003-08-20 2007-02-15 バイオサイト インコーポレイテッド 生物活性ナトリウム利尿ペプチドを測定するための、およびその治療可能性を向上させるための方法および組成物
US7355593B2 (en) * 2004-01-02 2008-04-08 Smart Technologies, Inc. Pointer tracking across multiple overlapping coordinate input sub-regions defining a generally contiguous input region
US20050163887A1 (en) * 2004-01-23 2005-07-28 Land O' Lakes, Inc. Method of producing heat stable whey protein and products made therefrom
BRPI0508181A (pt) * 2004-04-02 2007-08-07 Univ Tennessee Res Foundation componentes de laticìnio eficazes para a perda de gordura
ES2475207T3 (es) * 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
JP5070052B2 (ja) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
JP2008511678A (ja) * 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
EP1809759B1 (de) 2004-10-06 2013-09-11 The Brigham And Women's Hospital, Inc. Relevanz erzielter niveaus von markern für systemische entzündung nach behandlung
NZ537456A (en) * 2004-12-24 2007-10-26 Fonterra Co Operative Group Whey products and a process for preparing a modified whey protein concentrate
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
PL1851200T3 (pl) 2005-02-25 2014-06-30 Tetralogic Pharm Corp Dimeryczne inhibitory IAP
CA2604344A1 (en) * 2005-04-11 2006-10-19 University Of Tennessee Research Foundation Stable dairy components effective for fat loss
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
DK1906972T3 (da) 2005-07-19 2013-12-16 Univ Tennessee Res Foundation LPA2-receptoragonist til behandling af diarré
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007021825A2 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
JP2009518308A (ja) * 2005-12-01 2009-05-07 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション アポトーシスを阻害するための化合物及び方法
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014263A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049524A2 (de) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap-hemmer
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
WO2008060791A2 (en) * 2006-10-13 2008-05-22 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
US7842492B2 (en) 2007-01-05 2010-11-30 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
ES2527648T3 (es) 2007-06-08 2015-01-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar el subtipo de carcinoma hepatocelular
JP2009000091A (ja) * 2007-06-25 2009-01-08 Sanei Gen Ffi Inc 抱気性乳清タンパク質の調製方法及び該方法によって調製される食品
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
WO2009108745A1 (en) * 2008-02-26 2009-09-03 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
EP2257626A2 (de) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Behandlung, diagnostikum und verfahren zur entdeckung eines antagonisten unter verwendung sparc-spezifischer mirnas
CA2723716A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
EP2331103A1 (de) * 2008-09-22 2011-06-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Zusammensetzung eines nuklearfaktor-kappa-b-signalweghemmers und verwendung
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
EP2421899B1 (de) 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Antikörper gegen humanes ror1
ES2675236T3 (es) 2009-04-30 2018-07-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Schweinfurthinas y usos de las mismas
WO2010132532A1 (en) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
IN2012DN00352A (de) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
EP2287304A1 (de) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartige Behandlung von Patienten nach Stentimplantation oder Ballondilatation und neuartige Arzneimittel eluierende Stents
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
US8435795B2 (en) * 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
EP3178932A1 (de) 2011-02-03 2017-06-14 Mirna Therapeutics, Inc. Synthetische mimetika von mir-34
MX2013008944A (es) 2011-02-03 2014-01-08 Mirna Therapeutics Inc Mimeticos sinteticos de mir-124.
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9296818B2 (en) 2011-03-14 2016-03-29 Marene Inga-Britt Landstrom Cleavage inhibitors of transforming growth factor beta type I receptor and uses thereof in cancer therapy
ES2872077T3 (es) 2011-04-08 2021-11-02 Us Health Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
BR112013027057A2 (pt) 2011-04-21 2020-08-11 Trustees Of Tufts College composições e métodos para a estabilização de agentes ativos
CN106431988A (zh) 2011-06-14 2017-02-22 比卡姆药品公司 视蛋白结合配体、组合物及使用方法
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
EP2739734A1 (de) 2011-08-03 2014-06-11 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Behandlung von fibrose mit mikrorna-19b
CA2856703A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2851795C (en) 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
JP6126118B2 (ja) 2011-11-30 2017-05-10 ビカム ファーマスーティカルス，インコーポレイテッド オプシン結合性リガンド、組成物、及び使用方法
EP2785178B1 (de) 2011-12-01 2019-05-01 Bikam Pharmaceuticals, Inc. Opsinbindende liganden, zusammensetzungen damit und anwendungsverfahren dafür
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
US10076535B2 (en) 2012-04-27 2018-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing
JP6389166B2 (ja) 2012-05-07 2018-09-12 トラスティーズ・オブ・ダートマス・カレッジ 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
NZ702837A (en) 2012-06-15 2016-06-24 Morinaga Milk Industry Co Ltd Method for manufacturing modified whey composition, modified whey composition, and method for manufacturing calcium-enriched modified whey composition
CA2881818A1 (en) 2012-08-21 2014-02-27 Genesys Research Institute Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
JP6338252B2 (ja) 2012-10-24 2018-06-06 アメリカ合衆国 Ｍ９７１キメラ抗原受容体
EP2730170B1 (de) 2012-11-13 2016-02-10 DMK Deutsches Milchkontor GmbH Allergenfreie Nahrungsmittelzusammensetzungen
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
EP2971166B1 (de) 2013-03-14 2021-05-19 Children's Medical Center Corporation Psap peptide zur behandlung von cd36-exprimierenden krebs
KR102457668B1 (ko) 2013-03-15 2022-10-21 트러스티즈 오브 터프츠 칼리지 저분자량 실크 조성물 및 안정화 실크 조성물
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
EP2981280A2 (de) 2013-04-04 2016-02-10 IEO - Istituto Europeo di Oncologia Srl Thymus-stroma-lymphopoetin fragmente und verwendungen davon
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
EP3013329B1 (de) 2013-06-25 2020-08-05 The Walter and Eliza Hall Institute of Medical Research Smac mimetika zur behandlung von langwieriger intrazellulärer hbv-infektion
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
CA2928135A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
SG11201604565WA (en) 2013-12-06 2016-07-28 Us Health Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
MX374247B (es) 2013-12-16 2025-03-05 Soc Des Produits Nestle S A Star Peptidos identificados recientemente para el uso en la induccion de la tolerancia oral en mamiferos jovenes.
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
US10646541B2 (en) 2014-03-26 2020-05-12 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP4331618A3 (de) 2014-05-09 2024-06-12 Yale University Hyperverzweigte polyglycerolbeschichtete partikel und verfahren zur herstellung und verwendung davon
JP6613304B2 (ja) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗ｃｄ２７６抗体（ｂ７ｈ３）
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
BR112017026209A2 (pt) 2015-06-05 2018-11-27 Ibio, Inc. fragmentos e variantes de endostatinas para uso no tratamento de fibrose
US10633427B2 (en) 2015-06-26 2020-04-28 Prindex S.R.L. Diagnosis and therapy of multiple sclerosis
EP3313519B1 (de) 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat hemmer zur behandlung von kongenitalen myopathien
EP3763378A1 (de) 2015-08-06 2021-01-13 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
WO2017102257A1 (en) 2015-12-18 2017-06-22 Nestec S.A. Heat sterilized high protein compositions comprising whey protein and at least one component selected from (i) a saccharide, (ii) a phosphate and (iii) a citrate
CN109311982A (zh) 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
SG11201809100QA (en) 2016-04-19 2018-11-29 Us Health Use of gram negative species to treat atopic dermatitis
CA3023980A1 (en) 2016-05-16 2017-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
US11299546B2 (en) 2016-05-27 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services FLT3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018005759A1 (en) 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
JP6995827B2 (ja) * 2016-07-15 2022-01-17 アーラ フーズ エエムビエ 濃縮または乾燥酸ゲル化可能ホエータンパク質凝集体と、関連組成物および食品とを製造する方法
EP3595636A4 (de) 2017-03-16 2021-01-13 Children's Medical Center Corporation Gentechnisch hergestellte liposomen als zielgerichtete therapeutika gegen krebs
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
WO2019016392A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag HUMAN ANTIBODIES BINDING TO ROR2
EP3665193A1 (de) 2017-08-07 2020-06-17 NBE Therapeutics AG Auf anthracyclin basierende antikörper-wirkstoff-konjugate mit hoher in-vivo-verträglichkeit
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
WO2019189350A1 (ja) * 2018-03-30 2019-10-03 雪印メグミルク株式会社 κ－カゼイングリコマクロペプチドを含む組成物の製造方法
WO2019217203A1 (en) 2018-05-11 2019-11-14 Forte Biosciences, Inc Compositions for the treatment of skin conditions
PL3813549T3 (pl) 2018-06-27 2026-03-09 Arla Foods Amba Preparat napoju z beta-laktoglobuliną o obojętnym ph
CN109045278B (zh) * 2018-07-09 2022-06-21 苏州恒瑞健康科技有限公司 一种稳定的乳蛋白质液态体系及其应用
CA3114911A1 (en) 2018-10-04 2020-04-09 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2020081737A1 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Compositions and methods for inducing intestinal stem cell regeneration
EP3867365A1 (de) 2018-10-19 2021-08-25 Board of Regents, The University of Texas System Gentechnisch hergestellte transposons mit langem interspergiertem element (line) und verwendungsverfahren dafür
MX2021006182A (es) 2018-12-19 2021-06-18 Nestle Sa Composicion para prevenir o reducir la perdida de agua transepidermica y mejorar la funcion de barrera de la piel.
EP3677693A1 (de) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimäre gentranskripte (tcgts) als krebsbiomarker
PE20211977A1 (es) 2019-01-18 2021-10-05 Janssen Biotech Inc Receptores de antigenos quimericos de gprc5d y celulas que los expresan
EP3918607A1 (de) 2019-01-30 2021-12-08 Janssen Pharmaceutica NV Verfahren zur behandlung von prostatakrebs auf der basis molekularer subtypen
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
JP2022526194A (ja) 2019-04-10 2022-05-23 エレベートバイオ テクノロジーズ，インコーポレイテッド Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法
AU2020280105A1 (en) 2019-05-22 2022-01-20 Massachusetts Institute Of Technology Circular RNA compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
CN114174346B (zh) 2019-07-26 2025-08-01 詹森生物科技公司 抗hk2嵌合抗原受体(car)
CN114375302B (zh) 2019-07-26 2024-12-24 詹森生物科技公司 包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
JP2022544592A (ja) 2019-08-16 2022-10-19 ヤンセン バイオテツク，インコーポレーテツド 改善された機能を有する治療用免疫細胞及びその作製方法
PH12022551211A1 (en) 2019-11-18 2023-10-02 Janssen Biotech Inc Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
EP4084623B1 (de) 2019-12-30 2024-05-01 Arla Foods amba Verfahren zur herstellung von dichten molkeprotein-nanogelen, die resultierenden molkeprotein-nanogele oder nanogelzusammensetzungen und verwendung solche molkeprotein-nanogele oder nanogelzusammensetzungen
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (de) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitoren und verwendungen davon
AU2021225926A1 (en) 2020-02-26 2022-10-20 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
US20240293453A1 (en) 2020-03-13 2024-09-05 Janssen Biotech, Inc. Materials and methods for binding siglec-3/cd33
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
WO2021236855A1 (en) 2020-05-19 2021-11-25 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
JP2023554215A (ja) 2020-10-16 2023-12-27 ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド 糖共役体
KR20230160314A (ko) 2021-03-24 2023-11-23 얀센 바이오테크 인코포레이티드 Cd22 및 cd79b를 표적화하는 항체
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
EP4352226A1 (de) 2021-06-07 2024-04-17 Yale University Peptidnukleinsäuren zur räumlich-zeitlichen steuerung der crispr-cas-bindung
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
CA3228786A1 (en) 2021-08-25 2023-03-02 Ibio, Inc. Anti-cd25 antibody
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
TW202334080A (zh) 2021-11-08 2023-09-01 美商歐納醫療公司 用於遞送環狀聚核苷酸之脂質奈米粒子組合物
JP2025523368A (ja) 2022-05-30 2025-07-23 シャンハイ サーコード バイオメッド カンパニー，リミティド 合成環状ｒｎａ組成物及びその使用方法
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
EP4634390A2 (de) 2022-12-15 2025-10-22 Orna Therapeutics, Inc. Zirkuläre rna-zusammensetzungen und verfahren
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
AU2024269222A1 (en) 2023-05-05 2025-10-09 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
AU2024298726A1 (en) 2023-07-27 2026-02-19 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
EP4537907A1 (de) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248-inhibitoren und verwendungen davon
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1085380A (en) * 1913-03-28 1914-01-27 Adam Thomas Bell Whey emulsion.
US1609617A (en) * 1926-06-15 1926-12-07 William O Frohring Method of increasing the coagulating point of milk
US1954769A (en) * 1930-12-08 1934-04-10 M & R Dietetic Lab Inc Treating milk products
US2570231A (en) * 1946-01-04 1951-10-09 Hansen Francis Frederick Condensed milk composition and its preparation
US2555514A (en) * 1947-01-20 1951-06-05 Golden State Company Ltd Whey product derived from milk and process of producing same
FR1523106A (fr) * 1962-06-15 1968-05-03 Afico Sa Lait en poudre pour nourrissons et son procédé de fabrication
DE1692294A1 (de) * 1966-09-14 1971-07-29 United Brands Co Verfahren zur Stabilisierung kondensierter Milch
US3791283A (en) * 1970-08-28 1974-02-12 Gen Foods Corp Method for producing heat and acid stable whey protein material
DE2138277C2 (de) * 1971-07-30 1982-09-16 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Verfahren zur Herstellung eines Molkeeiweißkonzentrates
CH556143A (fr) * 1972-09-11 1974-11-29 Nestle Sa Procede de preparation d'une fraction soluble des proteines du petit lait.
NL7603369A (en) * 1976-03-31 1977-10-04 Stichting Bedrijven Van Het Selective removal of inorganic ions from aq. protein concentrates - by ultrafiltration and diafiltration at controlled pH
FR2391653A1 (fr) * 1977-05-23 1978-12-22 Nestle Sa Soc Ass Tech Prod Procede de traitement du lactoserum
NL181326C (nl) * 1979-11-20 1987-08-03 Stichting Bedrijven Van Het Werkwijze voor de bereiding van voedingsmiddelen waarin een in water oplosbare gedenatureerde wei-eiwitsamenstelling wordt opgenomen alsmede werkwijze ter bereiding van oplosbare gedenatureerde wei-eiwitsamenstellingen.
JPS603814B2 (ja) * 1981-10-02 1985-01-30 協和醗酵工業株式会社 改質ホエ−蛋白貿の製造法
US4460615A (en) * 1981-10-02 1984-07-17 Kyowa Hakko Kogyo Kabushiki Kaisha Process for improving the quality of whey protein
US4497836A (en) * 1982-08-06 1985-02-05 Dairy Technology Ltd. Modified whey product and process including ultrafiltration and demineralization

Also Published As

Publication number Publication date
GB8411196D0 (en) 1984-06-06
KE3728A (en) 1987-06-05
EP0126290B2 (de) 1994-03-30
SG35687G (en) 1988-09-23
US4748034A (en) 1988-05-31
JPS646739B2 (de) 1989-02-06
CA1200416A (en) 1986-02-11
ES8506983A1 (es) 1985-09-01
ES532469A0 (es) 1985-09-01
MX167579B (es) 1993-03-30
AU564405B2 (en) 1987-08-13
EP0126290B1 (de) 1987-01-07
HK73787A (en) 1987-10-16
DK235584D0 (da) 1984-05-11
AU2755184A (en) 1984-11-15
DE3461886D1 (en) 1987-02-12
NZ208086A (en) 1986-06-11
JPS59216544A (ja) 1984-12-06
EP0126290A1 (de) 1984-11-28
ZA843213B (en) 1984-12-24
MY100729A (en) 1991-01-31
GB2139630A (en) 1984-11-14
GB2139630B (en) 1987-01-07

Similar Documents

Publication Publication Date Title
ATE24658T1 (de) Verfahren zur herstellung eines molkeproduktes.
PH23256A (en) A process for the preparation of quinolone carboxylic acid derivatives
MA19639A1 (fr) Procede de preparation de derives de l'acide cis, endo-2-azabicyclo- (3,3,0) -octane-3- carboxylique et d'agents contenant ces derives
DE3567463D1 (en) 4-dimethylamino-1-hydroxybutane-1,1-diphosphonic acid, its water soluble salts, process for their preparation and its use
ATE11640T1 (de) Verfahren zur herstellung von blutgerinnungsfaktoren.
AU1810983A (en) Pasteurized human fibrinogen (HF), a process for its preparation and its use
DE2966967D1 (en) Milk substitutes and process for preparing them
DE3464849D1 (en) Stable, aqueous, acidic solution of cis-platinum, suitable for injection
ATE12064T1 (de) Methode zur herstellung eines produkts mit gehalt an geliertem, hydrolysiertem collagen.
ATE30844T1 (de) Verfahren zur herstellung der wichtigsten proteine des haemolysierten bluts in einer nichtdenaturierten form.
CA2040496A1 (en) Method for preparing an aqueous food supplement for cattle and thus prepared food supplement
IE801358L (en) Gelling of whey proteins.
ATE15853T1 (de) Methode zur herstellung eines gelierten nahrungsmittels.
SE8002126L (sv) Sett att framstella organextrakt med hog heparinhalt
NO174240C (no) Fremgangsmåte for sterilisering av en vandig suspensjon av et uopplöselig salt i vann, og anvendelse av den derved fremstilte suspensjonen for fremstilling av soyaost eller for tilsats av mineralsalter til næringsmidler
ES450053A1 (es) Un procedimiento para elaborar un producto de proteina tex- turizada.
BG31214A3 (en) Method for obtaining of human albumine
SE7900703L (sv) Stabil koncentrerad losning av glycidyltrimetylammoniumklorid samt metod for framstellning av sadana losningar
JPS5559146A (en) Isolation of phenylalanine
ZA885785B (en) Process for the preparation of n6-benzyloxycarbonyl-2,6-diaminopimelamic acid in the l,l or d,d or racemic forms
ES8505676A1 (es) Procedimiento para la preparacion del fosfato del (+) 14, 15-dehidro-(3 , 16 )-eburnamenina-14-carboxilato de etilo
ES8303048A1 (es) Procedimiento de fabricacion de pienso para ganaderia.
ATE46338T1 (de) Verfahren zur herstellung von 3-cephem-4 carboxylsaeure-derivaten, substituiert in position 3.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee